18. The use according to any one of claims 15-17 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).

19. The use according to any one of claim 15-18, wherein the antibody binds to CSF-1R.

20. The use according to any one of claims 12-19 where the fibrotic disease is idiopathic pulmonary fibrosis (IPF).

21. The use according to any one of claims 12-19 where the fibrotic disease is scleroderma.

22. The use according to any one of claims 12-19 where the fibrotic disease is renal fibrosis.

~~23. A method for the treatment and/or prophylaxis of fibrotic disease comprising administering a therapeutically effective amount of an inhibitor of CSF-1R activity.~~

~~24. The method according to claim 23, wherein the inhibitor is a small chemical entity (NCE).~~

~~25. The method according to claim 23, wherein the inhibitor is a nucleic acid.~~

~~26. The method according to claim 23, wherein the inhibitor is an antibody or functionally active fragment or derivative thereof.~~

~~27. The method according to claim 26, wherein the antibody or fragment thereof is monoclonal, polyclonal, chimeric, humanised or bispecific.~~

~~28. The method according to claim 26 or claim 27 wherein the antibody fragment is a Fab, Fab', $F(ab')_2$, scFv or epitope binding fragment thereof.~~

~~29. The method according to any one of claims 26-28 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).~~

~~30. The method according to any one of claim 26-19 wherein the antibody binds to CSF-1R.~~

~~31. The method according to any one of claims 23-30 wherein the fibrotic disease is idiopathic pulmonary fibrosis (IPF).~~

~~32. The method according to any one of claims 23-30 wherein the fibrotic disease is scleroderma.~~

~~33. The method according to any one of claims 23-30 where the fibrotic disease is renal fibrosis.~~

~~34.~~23. The ~~method~~ use according to any one of claims ~~23-33~~12-22 where the inhibitor of CSF-1R activity is to be administered in combination with one or more other therapeutically active compounds.

~~35.~~24. The ~~method~~ use according to claim ~~34~~ 23 in which the other therapeutically active compound is another anti-fibrotic therapeutic agent.